Canadian Ofloxacin Susceptibility Study: A Comparative Study from 18 Medical Centers

Abstract

Ofloxacin, a newer fluorinated 4-quinolone having a broad spectrum of activity was evaluated against 5,553 clinical pathogens isolated from urine, respiratory tract, skin and genital tract infections at 18 Canadian Medical Centers spread across the nation. Approximately 300 strains were reported (zone diameters) from each site. The zones of ofloxacin, other fluoroquinolones, oral cephalosporins and penicillins were analyzed and interpreted by NCCLS criteria. Ofloxacin had the widest spectrum of activity against gram-positive organisms and most gram-negative organisms, while ciprofloxacin was only superior for the Pseudomonas spp. The percentage of isolates susceptible to ofloxacin was as follows: for respiratory tract pathogens = 94%, for skin and soft tissue infections = 94%, for urinary tract organisms = 93% and for genital tract isolates = 94%.

Canadian ciprofloxacin susceptibility study: comparative study from 15 medical centers. Canadian Ciprofloxacin Study Group

“…The reduction in susceptibility of coagulase-negative staphylococci observed in this study is similar to that found by Hoban et al (6). Overall, susceptibility to ciprofloxacin was 90%, and this was identical to the rate reported by Hoban and Jones (5) and Hoban et al (6). Chamberland et al (1) did not find any ciprofloxacin-resistant P. aeruginosa isolates, while Hoban et al (6) found a 4 to 10% incidence of resistance in isolates from Canadian medical centers.…”

“…The results of their study appear to be similar to those of the current study. The reduction in susceptibility of coagulase-negative staphylococci observed in this study is similar to that found by Hoban et al (6). Overall, susceptibility to ciprofloxacin was 90%, and this was identical to the rate reported by Hoban and Jones (5) and Hoban et al (6).…”

“…Overall, susceptibility to ciprofloxacin was 90%, and this was identical to the rate reported by Hoban and Jones (5) and Hoban et al (6). Chamberland et al (1) did not find any ciprofloxacin-resistant P. aeruginosa isolates, while Hoban et al (6) found a 4 to 10% incidence of resistance in isolates from Canadian medical centers. Coronado et al (3) reported that 4.7% of 8,517 P. aeruginosa isolates collected between 1989 and 1992 and reported to the National Nosocomial Infections Surveillance System were resistant to ciprofloxacin, and Tillotson et al (11) reported an increase (1.4 to 11.1%) in the occurrence of ciprofloxacin-resistant P. aeruginosa in the United Kingdom over a 6-year period.…”

“…On the basis of the results of a 15-medical-center survey using fresh clinical isolates, susceptibilities of S. aureus and Enterobacteriaceae to ciprofloxacin were similar to susceptibility data determined by Hoban et al (6) (11) concluded that after 6 years of ciprofloxacin use, little resistance has emerged among Enterobacteriaceae and H. influenzae. The results of their study appear to be similar to those of the current study.…”

“…Hoban and Jones, using data from five North American medical centers (5), reported that susceptibility of members of the family Enterobacteriaceae to ciprofloxacin ranged from 95 to 100%, that of Staphylococcus aureus ranged from 14 to 96%, that of coagulase-negative staphylococci ranged from 55 to 91%, that of Streptococcus pneumoniae was 85%, that of P. aeruginosa was 85%, and those of Haemophilus influenzae and Moraxella catarrhalis were 100%. We undertook a Canada-wide, 15-medical-center survey to deter-mine the in vitro activities of ciprofloxacin and several other antimicrobial agents against gram-positive and gram-negative pathogens and compared these findings with those collected from previous surveys (1,5,6,12).…”